Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
In several ocular diseases, the vascular endothelial growth factor (VEGF) level has been found to be upregulated. Bevacizumab, an anti-VEGF drug, is the most commonly used off level drug for these conditions. Delivery of drug to the posterior site is desired for the effective management of these diseases. The present study was to develop and optimize the chitosan (CS)-coated poly(lactide-co-glycolic acid) (PLGA) nanoparticles (NPs) of bevacizumab for sustained and effective delivery to posterior ocular tissues. NPs were prepared by double emulsion solvent evaporation method and optimized for various variables (i.e., CS concentration, PLGA content, polyvinyl alcohol (PVA) concentration, and sonication time) by employing a 4-factor 3-level Box–Behnken statistical design. NPs were characterized for particle size, polydispersity index (PDI), entrapment efficiency (EE), and in vitro release. Transscleral flux was determined through goat sclera, and ocular tolerance assay was done by Hen’s Egg Test chorioallantoic membrane method. The particle size and PDI of the optimized NPs were 222.28 ± 7.45 nm and 0.19 ± 0.08, respectively. The developed NPs showed an EE of 69.26 ± 1.31% with an extended release profile. The flux was significantly higher that is, 0.3204 ± 0.026 μg/cm2/h for the NPs compared to drug solution. Thus, CS-coated PLGA NPs can be potentially useful as ocular drug carriers to target retina.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 2×
“There are four active isomers of VEGF-A consisting of 121, 165, 189, and 206 amino acids (Ferrara et al. 2003).”
BackgroundCheung, N., Mitchell, P., & Wong, T. Y. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62124-3 · Cited by 3,288
Chitosan-Modified PLGA Nanoparticles with Versatile Surface for Improved Drug Delivery
Wang, Y., Li, P., & Kong, L. (2013) · AAPS PharmSciTech · doi:10.1208/s12249-013-9943-3 · Cited by 305
Lamprecht, A., Ubrich, N., Hombreiro Pérez, M., Lehr, C.-M., Hoffman, M., & Maincent, P. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00422-6 · Cited by 185 · cited 1×
“With the rise in polymer concentration in organic phase (PLGA) from 2mg/mL to 5mg/mL, the NPs become larger in size as reported in earlier work (Lamprecht et al. 2000).”
Cited by
Xu, M., Fan, R., Fan, X., Shao, Y., & Li, X. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s383101 · Cited by 111
Mehra, N., Aqil, M., & Sultana, Y. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105735 · Cited by 79
Beygi, M., Oroojalian, F., Hosseini, S. S., Mokhtarzadeh, A., Kesharwani, P., & Sahebkar, A. (2023) · Progress in Materials Science · doi:10.1016/j.pmatsci.2023.101209 · Cited by 32
RetractedAnsari, M., Gupta, C., Kulkarni, Y. A., & Singh, K. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125235 · Cited by 10
Kailasam, V., Malani, M., & Nirmal, J. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126162 · Cited by 3
Metadata
- Authors
- Pandit, J., Sultana, Y., & Aqil, M.
- Venue
- Artificial Cells, Nanomedicine, and Biotechnology
- Publisher
- Informa UK Limited
- Published
- 2016-11-18
- Volume
- 45
- Issue
- 7
- Pages
- 1397-1407
- ISSN
- 2169-1401 (ISSN-L)
- 2169-141X
- OpenAlex
- W2552601893
- Cited by
- 134
- References
- 4
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation. https://app.cochat.ai/papers/10.1080/21691401.2016.1243545
- The paper
- Pandit, J., Sultana, Y., & Aqil, M. (2017). Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation. Artificial Cells, Nanomedicine, and Biotechnology. https://doi.org/10.1080/21691401.2016.1243545
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.